Every 424B that Tenon Medical, Inc. (TNON) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TNON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNON filings page.
Tenon Medical, Inc. (TNON) amended its ATM prospectus to permit it to offer and sell common stock with an aggregate offering price of up to $7,176,045 under its sales agreement with A.G.P./Alliance Global Partners, acting as sales agent or principal. This amount excludes $2,809,378 of common stock sold under the agreement during the 12 calendar months through October 16, 2026.
While public float remains below $75.0 million, Tenon's public primary offerings on Form S-3 are limited to one-third of public float in any 12 calendar month period. As of October 16, 2026, the aggregate market value of common stock held by non-affiliates was $29,956,270, calculated using 2,625,440 shares and a price of $11.41 per share, the August 19, 2026 closing price and highest closing sale price in the prior 60 days. If public float exceeds $75.0 million, the limit no longer applies; if an increase permits additional sales, Tenon says it will file another prospectus supplement before making them.
Tenon Medical, Inc. (TNON) registered 858,269 shares of common stock for resale by Armistice Capital Master Fund Ltd.; the shares are issuable upon exercise of September 2026 Series B warrants. Tenon is not selling shares under the prospectus and receives no proceeds from resales. It may receive up to $4,308,510 in aggregate gross proceeds from cash exercises at $5.02 per share; net proceeds are intended for working capital, capital expenditures and other general corporate purposes.
Under the September 14, 2026 inducement transaction, the holder agreed to cash-exercise 572,179 existing warrants at $5.02 per share in exchange for new warrants to purchase up to 858,269 shares. The new warrants are immediately exercisable, expire five years after issuance and restrict exercise above 4.99% ownership; that limit may be increased to no more than 9.99% with at least 61 days’ prior notice. Assuming exercise of the September 2026 warrants, 3,547,004 common shares would be outstanding after the offering.
Haskell & White LLP’s report on Tenon’s 2025 and 2024 financial statements included an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.
Tenon Medical, Inc. is offering 5,526,315 shares of common stock on a reasonable best efforts basis, together with Common Warrants to purchase up to 13,263,159 shares and Pre-funded Warrants to purchase up to 5,526,316 shares, at a combined public offering price of $0.38 per share and accompanying Common Warrants.
The prospectus states the offering is being conducted through WallachBeth Capital LLC as sole placement agent and is expected to close in a single fixed-price closing. Gross proceeds are shown as $4.2 million with estimated net proceeds of approximately $3.62 million, intended for repayment of convertible notes and commercial expansion, among other corporate purposes.